

**DFW-APIC Government Affairs Committee
Feb 2021**

APIC Public Policy and E-News Highlights (2021-2022)

<http://cqrcengage.com/apic/home>

<http://apic.org/Member-Services/Publications/E-News>

| | |
|----------|--|
| 2/3/2021 | OSHA Issues Stronger Workplace Guidance on COVID-19 in response to President Biden's direction to OSHA to release clear guidance for employers to keep workers safe from COVID-19 exposure. |
| 2/3/2021 | USP COVID-19 Vaccine Handling Toolkit to provide critical information to healthcare providers who are involved in handling COVID-19 vaccines. |
| 2/3/2021 | CDC has released the first seven "Inside Infection Control" videos. These short (mostly under five minutes) videos are intended to provide basic infection control principles for non-IP frontline healthcare personnel. See the Project Firstline videos and other resources. |
| 2/3/2021 | The CDC released its antibiotic resistance investment map to reflect more than \$118 million in investments to all 50 states and other partners around the world in FY 2020 to combat antibiotic resistance. The interactive map also features printable global-, state-, and city-specific fact sheets. The AR Investment Map , along with other resources, are available on the CDC Antibiotic Resistance Website . |
| 2/3/2021 | The FDA placed all alcohol-based hand sanitizers from Mexico on a country-wide import alert to help prevent entry of violative and potentially dangerous products from entering the U.S. |
| 2/3/2021 | In order to allow hospitals to focus on patient care during the COVID-19 public health emergency, CMS has instituted limitations on hospital surveys for a 30-day period beginning January 20, 2021, with potential for 30-day renewals following additional notice. |
| 2/3/2021 | The FDA is reissuing the Emergency Use Authorizations (EUAs) for decontamination systems that are authorized to decontaminate compatible N95 respirators for use by healthcare personnel (HCP) to prevent exposure to pathogenic biological airborne particulates when there is an insufficient supply of new respirators resulting from the Coronavirus Disease 2019 (COVID-19) pandemic. Among other things, the reissued EUAs for certain decontamination systems are now only authorized to decontaminate each compatible N95 respirator a maximum of four or fewer times. |
| 2/3/2021 | The FDA is alerting clinical laboratory staff and healthcare providers that the FDA is monitoring the potential impact of viral mutations on authorized SARS-CoV-2 molecular tests, and that false negative results can occur with any molecular test for the detection of SARS-CoV-2 if a mutation occurs in the part of the virus's genome assessed by that test. The FDA is taking additional actions to ensure authorized tests remain accurate by working with test developers and conducting ongoing data analysis to evaluate all currently authorized molecular tests. The FDA believes the risk that these mutations will impact overall testing accuracy is low. Read the FDA alert . Read the FDA letter to healthcare providers and laboratory staff |

Texas Register (2021-2022)

<http://www.sos.state.tx.us/texreg/index.shtm>

Key: X Pending

Last Review Completed: 1/29/2021

Current Search Parameters

for Review:

25 TAC: Chapters 2, 97, 133,
135, 200

30 TAC: Chapter 330;

Subchapter Y

| X | Date Filed | Action | Title/Ch./Rules/SB/H B | Topic / Comments |
|-----|------------|--------|---------------------------|------------------|
| N/A | N/A | N/A | N/A | N/A |

Prepared by 2020 APIC-DFW Governmental Affairs Committee:
Jasmine Cluck, Heather Kirby, Patti Grant, Stephanie Kreiling